Topic: HPV · Cervical precancer · Post-treatment surveillance

HPV 16/18 and CIN2 After LEEP, Now Testing Negative: What It Means, How Much the Vaccine Helps, How Long to Keep Testing and What It Means for Pregnancy

AI Overview / Quick Answer (BLUF)

A negative HPV test and normal Pap after LEEP mean the virus is not detectable now: residual CIN2+ risk is about 0.8%, not zero. Vaccination after excision lowers recurrence mainly by blocking reinfection. Keep testing at 6, 18 and 30 months, then every 3 years for 25+ years.

Who this is for:
people who had high-risk HPV (NCI) type 16/18 with a CIN2 lesion, were treated with a loop electrosurgical excision procedure (LEEP), and whose latest tests are negative ·
if you are still before treatment, read
From CIN 1 to CIN 3 with HPV 16/18 and LEEP ·
Warning signs ·
Follow-up schedule ·
Vaccine evidence ·
Options compared ·
FAQ

A story from a women’s health group: two LEEPs, three vaccine doses, and now no virus detected

Short answer: this is genuinely good news and shows the step-by-step treatment worked. But one negative result is not the finish line; the next step is completing follow-up testing on schedule.

A member of a women’s health group shared that she had HPV 16/18 with CIN2, underwent two LEEPs, completed three doses of HPV vaccine and kept looking after her health until her latest HPV test was negative and her Pap was normal. This article explains what that result means, what actually helps according to the evidence, and what comes next. It does not assess her personal history, so it is not a diagnosis.

1. What a negative HPV test after LEEP means, and how much risk remains

Short answer: a negative HPV test after treatment is the most accurate marker of success, more accurate than the excision margins, but long-term risk stays higher than in people who never had a lesion.

0.8%Risk of CIN2+ when the post-treatment HPV test is negative
3.7%The same risk when judged only by clear excision margins
91%Sensitivity of HPV testing for residual disease, versus 55.8% for margins
6.6%Overall residual or recurrent CIN2+ after cervical excision

Negative means not detected, not absent

A pooled analysis of 97 studies and 44,446 women (Arbyn 2017) found positive margins in 23.1% of excisions (25.9% for LEEP). Overall residual or recurrent CIN2+ was 6.6%, and 4.8 times higher with involved margins.
When the post-treatment HPV test was negative, however, the risk fell to 0.8%, lower than with clear margins alone (3.7%). That is why international guidance relies on HPV testing for follow-up.

Why persistence, not a single positive, is what matters

A US National Cancer Institute study (Rodríguez 2008) followed 800 high-risk HPV infections: 67% cleared within 12 months, but infections that persisted 12 months or longer led to CIN2+ within 30 months in 21%. Post-treatment testing exists to catch a returning, persistent infection as early as possible.

Long-term risk stays above average

A Swedish cancer-registry study of 132,493 women treated for CIN3 (Strander 2007) found a 2.34-fold higher risk of cervical cancer than in the general population, still raised after 25 years and more marked after age 50.
A follow-up study of 150,883 women (Strander 2014) found a 2.35-fold higher risk of dying from cervical or vaginal cancer, accelerating after age 60, and the authors proposed lifelong surveillance. These data come from women treated for CIN3, so they describe people with prior high-grade lesions as a group, not any one person’s exact risk.

2. HPV vaccination after LEEP: it lowers recurrence but does not clear existing virus

Short answer: pooled studies show roughly 57–62% fewer CIN2+ recurrences in vaccinated people, mainly by preventing new infection or reinfection, but certainty of the evidence is still limited.

Figures are relative risks (RR); the further below 1, the larger the reduction (shown as cards on mobile)

Meta-analyses of HPV vaccination combined with cervical excision
StudyData sizeEffect on recurrent CIN2+What to know
Kechagias, BMJ 202211 studies, 19,909 people, median follow-up 36 monthsRR 0.43; RR 0.26 for HPV 16/18-related diseaseVery low to moderate certainty; no benefit shown for persistent infection
Jentschke, Vaccine 202010 studies, 21,059 peopleRR 0.41; RR 0.37 for HPV 16/18About 45.5 people vaccinated to prevent one recurrence
Maiorano, Front Oncol 202617 studies, 33,181 peopleRR 0.38, a 62% reductionSimilar with clear (RR 0.34) and involved (RR 0.40) margins; works mainly by preventing new infection

Why the vaccine does not clear leftover virus

HPV vaccines raise antibodies against the outer shell of the virus, which neutralize it before it enters a cell. Cells that are already infected do not display that shell to the immune system. The 2026 analysis (Maiorano 2026) therefore concluded the vaccine works mainly by preventing new infection or reinfection, not by clearance, and Kechagias 2022 found no evidence that vaccination reduces persistent infection.
A negative result like this one most likely reflects removal of the lesion plus the body’s own immune clearance; the vaccine is the shield against the next round.

Before or after surgery, and which vaccine type

The 2026 analysis found no clear difference between vaccinating before or after surgery, or between bivalent, quadrivalent and nonavalent vaccines (RR 0.50, 0.37 and 0.41), and no new safety signals. People who completed the series do not need to repeat it; those not yet vaccinated should discuss age, number of doses and cost with their doctor. More in
HPV vaccine after infection.

Check whether your follow-up still has gaps

Treated for cervical precancer and unsure when your next test is due, or whether a symptom means you should be seen sooner?

Get a severity analysis and personalized guidance from our Advisory team. The assessment sorts urgency and screening gaps; it does not diagnose any disease and does not replace an examination by your doctor.

Take the free Cervical Screening-Gap Assessment

3. Follow-up after treatment for CIN2+: 6-18-30 months, then every 3 years

Short answer: ASCCP guidance (updated through 2023) recommends three negative HPV tests or cotests at 6, 18 and 30 months before moving to every 3 years, and ASCCP 2019 advises continuing for at least 25 years.

Actual schedules depend on your doctor and the tests available locally (shown as cards on mobile)

Follow-up timing, the test used, and what happens with each result
TimingTestIf negativeIf positive or abnormal
6 months after treatmentHPV DNA test or HPV-plus-Pap cotestNext test in 12 monthsColposcopy and biopsy as your doctor advises
18 and 30 monthsHPV DNA test or cotestAfter three negatives, move to every 3 yearsColposcopy; repeat excision may be needed for a high-grade lesion
Every 3 yearsHPV DNA test or cotestContinue for at least 25 years from treatmentBack to colposcopy assessment
Over age 65Keep testing every 3 years if 25 years are not complete or health is goodDo not stop only because you reached the general screening age limitFurther assessment by a gynecologist

4. Two LEEPs and pregnancy: higher preterm-birth risk, but most women can still have children

Short answer: repeat cervical excision clearly raises the risk of preterm birth. It does not mean you cannot get pregnant; it means your obstetrician should know from the first antenatal visit.

The numbers

A pooled analysis of 71 studies (Kyrgiou 2016) found preterm birth before 37 weeks in 10.7% of treated women versus 5.4% (RR 1.78); for LEEP specifically, RR 1.56.
Women treated more than once delivered preterm in 13.2% versus 4.1% (RR 3.78), and deeper cones carried more risk, because less of the supportive collagen and protective mucus-producing glands of the cervix remains.

If you plan to have children

  • Tell your obstetrician at the first antenatal visit that you had two LEEPs, and bring pathology reports or excision depth if available
  • Your doctor may measure cervical length by ultrasound in the second trimester if appropriate
  • Learn the signs of preterm labor and waters breaking listed in the warning-signs section above
  • Cervical screening can continue during pregnancy as scheduled, but HPV vaccination is postponed until after delivery

5. Vitamins, smoking and partners: what helps and what lacks evidence

Short answer: no vitamin or supplement has been shown to clear HPV. Better-supported steps are stopping smoking, supporting overall immune health and testing on schedule.

Vitamins and supplements

A review of 77 studies from 17 countries (Li 2025) found that higher folate, vitamin B12, and vitamins A, D and E were associated with less viral persistence and fewer lesions. But most studies were case-control or cross-sectional, with only 7 randomized trials, so they show association, not proof that supplements clear the virus.
Eating enough vegetables, fruit and protein is a sound foundation; buying expensive supplements in the hope of clearing HPV is not supported by evidence. More in Probiotics and vitamins for HPV.

Smoking and immunity

The US National Cancer Institute (NCI) lists smoking and weakened immunity as co-factors that make HPV more likely to persist and progress. Stopping smoking, sleeping enough and controlling conditions such as diabetes are practical, reasonable steps.

Partners and preventing new infection

HPV spreads through skin contact. Condoms lower the risk but do not cover everything, and there is no routine standard HPV test for men. A new partner raises the chance of new infection; partner vaccination depends on age and a conversation with a doctor. More in How to tell a partner after a positive HPV result.

6. Options after treatment compared: surveillance, vaccination, repeat surgery and self-care

Short answer: HPV DNA surveillance is the backbone, vaccination is the add-on with the best evidence, and repeat surgery is only for a confirmed recurrence.

Options compared using generic names and vaccine types only (shown as cards on mobile)

Option, who it suits, strength of evidence and what to know
OptionWho it suitsEvidenceWhat to know
HPV DNA test or cotest on scheduleEveryone after treatment for CIN2+High; a negative test leaves about 0.8% riskContinue for at least 25 years
Nonavalent HPV vaccine (or bivalent/quadrivalent)Those not yet vaccinated, by age and doctor’s adviceModerate; about 57–62% fewer recurrencesPrevents new infection; does not clear existing virus
Colposcopy and biopsyA positive follow-up HPV test or abnormal PapStandard way to confirm a lesionOne positive test does not always mean a lesion
Repeat excision (LEEP or cone)A recurrent high-grade lesionEffective treatmentEach repeat raises preterm-birth risk
HysterectomySelected cases with recurrent lesions who do not want childrenNot a treatment for HPV aloneVaginal testing may still be advised
Stop smoking, sleep, manage chronic conditionsEveryoneReasonable, based on NCI-listed co-factorsDoes not replace follow-up testing
Vitamins and supplements (folate, B12, vitamins D and E)People with a confirmed deficiencyLow; mostly observationalNone proven to clear HPV

Frequently asked questions (FAQ)

Questions people treated for HPV 16/18-related cervical precancer often ask once their results return to normal

Does a negative HPV test and a normal Pap after LEEP mean the virus is gone?

It means the virus is not detectable at that moment, which is very good news. A pooled analysis of 97 studies found that a negative HPV test after treatment leaves a risk of residual or recurrent CIN2+ of about 0.8%. That is low but not zero, because the virus can stay below the detection limit or a new infection can occur, so follow-up testing still matters.

What does HPV vaccination after LEEP do, and can it clear leftover virus?

The vaccine does not clear an infection that is already present; it helps prevent new infection or reinfection. A 2022 BMJ meta-analysis found that vaccinated people had about 0.43 times the risk of recurrent CIN2+, and 0.26 times for HPV 16/18-related disease, but the certainty of evidence was very low to moderate. A 2026 meta-analysis concluded the main mechanism is preventing new infection rather than clearance.

After a normal result, how often do I need follow-up tests and for how many years?

ASCCP guidance recommends an HPV test or HPV-plus-Pap cotest at 6, 18 and 30 months after treatment. After three negative results you can move to testing every 3 years, continuing for at least 25 years, even beyond age 65. Your own schedule may differ depending on your doctor and the test used locally, so follow your doctor’s appointments.

I have had two LEEPs. Will that affect pregnancy?

It raises the risk of preterm birth. A 2016 BMJ meta-analysis of 71 studies found that women treated more than once delivered before 37 weeks in 13.2% of pregnancies versus 4.1% in untreated women, and deeper excisions carried more risk. Most women still conceive and deliver. If you plan a pregnancy or are pregnant, tell your obstetrician about both LEEPs so cervical length can be monitored if appropriate.

Can vitamins or supplements make HPV go away or stop it coming back?

No vitamin or supplement has been shown to clear HPV or prevent recurrence. A 2025 review of 77 studies found that higher levels of folate, vitamin B12, and vitamins D and E were associated with less viral persistence, but most of the studies were observational. A balanced diet supports general health, but it cannot replace vaccination or follow-up testing.

Can HPV 16/18 come back, and what happens if it does?

Yes. Virus hiding below the detection limit can multiply again, or a new infection can occur. Pooled data show an overall residual or recurrent CIN2+ rate of about 6.6% after excision. If a follow-up test turns positive, doctors usually perform colposcopy and biopsy to check for a lesion, and some people need another excision. That is why keeping appointments matters: it catches recurrence early.

After a normal result, can I have sex as usual, and should my partner be tested or vaccinated?

Once the cervix has healed and your doctor agrees, you can have sex as usual. Condoms lower the risk of infection but cannot prevent it fully, because HPV spreads through skin contact in areas condoms do not cover. There is currently no routine standard HPV test for men, and partner vaccination depends on age and a conversation with a doctor. A new partner raises the chance of new infection, which is another reason to keep testing.

Why do people treated for cervical precancer need testing even after age 65?

Because their long-term risk stays higher than average. A Swedish study of 132,493 women treated for CIN3 found a 2.34-fold higher risk of cervical cancer that was still raised after 25 years. A follow-up study of 150,883 women found a 2.35-fold higher risk of dying from cervical or vaginal cancer, accelerating after age 60. The researchers recommended lifelong surveillance.

Scientific mechanism

Summary by :
HPV 16/18 enters basal cells of the cervical transformation zone through micro-abrasions and produces the E6 and E7 proteins, which disable the cell-cycle regulators p53 and pRb. With long-lasting infection, cells become abnormal and form a CIN2 lesion. LEEP removes the transformation zone containing the lesion and most infected cells; the small amount of virus left is usually cleared by cell-mediated immunity, so the HPV test turns negative.
The virus can, however, remain in basal cells below the detection limit and multiply again when immunity dips. Vaccines induce antibodies against the L1 protein that transude into cervical mucus and neutralize virus before it enters cells, but already-infected cells do not display L1, so vaccination prevents new infection rather than treating existing infection.
Repeat excision removes more of the collagen that supports a pregnancy and the mucus-producing glands that block bacteria from reaching the amniotic sac, which is why preterm-birth risk rises with excision depth and number.

Academic citations (E-E-A-T)

  1. Kechagias KS, et al. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis. BMJ 2022.
  2. Jentschke M, et al. Prophylactic HPV vaccination after conization: a systematic review and meta-analysis. Vaccine 2020.
  3. Maiorano MFP, et al. Impact of HPV vaccine on CIN2+ recurrence after conization: a systematic review and meta-analysis of vaccination timing, valency and surgical margins. Front Oncol 2026.
  4. Arbyn M, et al. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol 2017.
  5. Strander B, et al. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 2007.
  6. Strander B, et al. Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3. BMJ 2014.
  7. Kyrgiou M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ 2016.
  8. Perkins RB, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023. J Low Genit Tract Dis 2024.
  9. Perkins RB, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2020.
  10. Rodríguez AC, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008.
  11. Li Y, Zhu L. The influence of nutrition on HPV-associated inflammation: a systematic review and meta-analysis. Front Nutr 2025.

Compiled and reviewed by · Generic names and vaccine types only; no trade names of drugs, vaccines or products.

Medical Disclaimer

This article is educational information based on research and international clinical guidelines. It is not a diagnosis, not a treatment prescription and not a substitute for seeing a doctor. Your actual follow-up schedule depends on your pathology, excision margins, test type and your doctor’s judgment. Do not postpone or cancel follow-up tests yourself because your latest result was normal. If you have abnormal bleeding or any warning sign, see a doctor promptly, and for heavy bleeding call emergency services.